Stock Market Reviews

VRTX (Vertex Pharmaceuticals Incorporated) News

Get the latest news, insights, and market updates on VRTX (Vertex Pharmaceuticals Incorporated). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• 1 Large-Cap Stock to Consider Right Now and 2 Facing Challenges
  Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
  Dec 9, 2025 - $VRTX
• Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?
  The stock has fallen from a peak back in April.
  Dec 7, 2025 - $VRTX
• Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”
  Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]
  Dec 6, 2025 - $VRTX
• Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
  BOSTON, December 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with sev
  Dec 6, 2025 - $VRTX
• Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?
  Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 5, 2025 - $VRTX
• Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX)
  Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI […]
  Dec 4, 2025 - $VRTX
• Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says
  Sionna Therapeutics' (SION) valuation topping $2 billion is "too optimistic" as the company's early-
  Dec 4, 2025 - $VRTX
• Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates
  Vertex Pharmaceuticals has seen its fair value estimate inch up from about $480 to roughly $485 per share as analysts refresh their models around a more constructive long term growth narrative. Underpinning this shift, research teams are nudging up assumptions for revenue growth while modestly raising the discount rate to reflect a slightly higher perceived risk profile as the story broadens beyond cystic fibrosis. Stay tuned to see how you can track these evolving assumptions and keep ahead...
  Dec 4, 2025 - $VRTX
• Vertex Pharmaceuticals (VRTX): Assessing Valuation After Recent Multi-Month Share Price Gains
  Vertex Pharmaceuticals (VRTX) has quietly added to recent gains, with shares up around 10% over the past month and roughly 17% in the past 3 months, drawing fresh attention to its long term growth story. See our latest analysis for Vertex Pharmaceuticals. At around $463 per share, Vertex’s recent 1 month share price return of nearly 10% and 3 month share price return of about 17% signal building momentum on the back of steady pipeline progress and solid earnings growth, supported by a robust...
  Dec 4, 2025 - $VRTX
• 1 Reason I'll Never Sell Vertex Pharmaceuticals Stock
  The stock has climbed in the double-digits in recent years.
  Dec 4, 2025 - $VRTX